Search
Leading paediatrician, infectious diseases specialist and Executive Director of The Kids Research Institute Australia, Professor Jonathan Carapetis, has been recognised for his significant contribution towards medical research with the award of Member of the Order of Australia (AM).
The World Health Organisation resolution for global action to tackle rheumatic heart disease (RHD) will have significant implications for Australia, which has some of the highest rates of the disease in the world.
In a WA first, researchers from The Kids Research Institute Australia have shown that Aboriginal babies are 22.5 times more likely to be treated for skin infections than non-Aboriginal babies.
Some of the nation’s leading medical researchers will converge on Darwin this week to step out a plan to wipe out rheumatic heart disease.
Researchers at The Kids Research Institute Australia say Group A Streptococcus should become a nationally notifiable disease in Australia.
Researchers at The Kids Research Institute Australia have begun a comprehensive research project into vaccines aimed at tackling rheumatic fever.
The prevalence of impetigo and pharyngitis - which are both superficial group A streptococcus (GAS) infections that precede acute rheumatic fever - is poorly defined. Guidelines recommend the early diagnosis of both infections to prevent ARF; however, screening to enable the concurrent detection of these infections in high-risk populations has rarely been performed.
We have read with interest the new publication by Rouhiainen and colleagues on missed opportunities for preventing or diagnosing acute rheumatic fever (ARF).
Fear of severe adverse reaction (SAR) and reluctance of health care providers to administer intramuscular injections are major contributing factors to poor adherence of benzathine penicillin G (BPG) in the management of rheumatic heart disease (RHD). However, data on the risk of SARs following BPG injections for RHD are relatively limited and inconclusive. Our systematic review and meta-analysis aimed to evaluate the incidence of SARs associated with BPG injections used for secondary prophylaxis of RHD.
Although benzylpenicillin (penicillin G) is listed by the World Health Organization as an Essential Medicine, dose optimization is a persistent challenge, especially for long-acting intramuscular formulations. Maintaining sustained antibiotic exposure at target concentrations is crucial for secondary chemoprophylaxis of rheumatic heart disease and treatment of syphilis.